Eli Lilly and Company

Lilly Icos LLC

Other

University of East Anglia

Jason Scott Sawyer

Douglas Wade Beight

Robert T Shuman

Michael Robert Wiley

John Joseph Masters

Ying Kwong Yee

Gerald Floyd Smith

Steven E Hall

James Howard Wikel

David Kent Herron

Valentine Joseph Klimkowski

David Mendel

Jennifer Marie Tinsley

Anne Louise Tebbe

Leonard Crayton Weir

Trelia Joyce Craft

Mark W Orme

Theodore Goodson, Jr

Jeffry Bernard Franciskovich

Guy Milot

Jeffrey Alan Kyle

John Michael Morin, Jr

Daniel Jon Sall

Sajan Joseph

Lisa M Schultze

Michael Dean Kinnick

Ho-Shen Lin

Michael Enrico Richett

Alain Claude-Marie Daugan

William Thomas McMillen

Edward C R Smith

Hong-Yu Li

Nicholas J Bach

Michael Lyle Denney

Yan Wang

Marta Maria Pi&ntilde;eiro-N&uacute;&ntilde;ez

Edward David Mihelich

William T Jackson

Jerome H Fleisch

Jonathan Michael Yingling

Stephen Richard Baker

James Robert Henry

Jeremy Gilmore

Russell Andrew Lewthwaite

Alexander McKillop

Joyce Z Crich

George Richard Stephenson

Raymond F Brown

Agnes Bombrun

Carl Penman Denny

Timothy Paul Burkholder

Jolie Anne Bastian

Richard Waltz Harper

Robert D Dillard

Michael LeRoy Phillips

Sushant Malhotra

Benjamin Alan Anderson

Susan Elizabeth Draheim

Tulio Suarez

Alexander Glenn Godfrey

Robert Theodore Vasileff

Thomas Albert Engler

Romain Luc Marie Gosmini

Nancy Kay Harn

Gary A Hite

Richard Walter Schevitz

John Mcneill McGill, Iii

Delu Jiang

Hong Hu

Melissa Kate Slater

Clive Gideon Diefenbacher

Romain Luc Gosmini

Françoise Jeanne Gellibert

Marta Maria Pi&ntilde;eiro-Nu&ntilde;ez

Huaxing Pei

Richard James Loncharich

Theodore Goodson, Junior

Michael William Urquhart

David Andrew Coates

John E Toth

Rosanne Bonjouklian

Jeremy Schulenburg York

Shawn Christopher Miller

Joshua Ryan Clayton

Chi-Hsin Richard King

Gaiying Zhao

Mary Margaret Mader

Michael Lawrence Sierra

Junkai Liao

Brandon Lee Parkhurst

Nerina Dodic

James Denmore Copp

Marta Maria Pineiro-Nunez

James J Starling

Kenneth James Henry, Jr

Harold Burns Brooks

Francoise Jeanne Gellibert

Stephen M Spaethe

Craig Daniel Wolfangel

Douglas Webb Johnson

The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of transforming growth factor beta receptor 1 (TGF&#x3b2;R1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, preferably colon cancer, melanoma, hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer, and gastric cancer, and/or fibrosis, preferably liver fibrosis and chronic kidney disease.

Aminopyridyloxypyrazole compounds

The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I. 

AKT inhibitors

The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.

Triazolyl aminopyrimidine compounds

The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: Ris aminomethyl, (C-Calkyl)aminomethyl, di(C-Calkyl)aminomethyl, N-ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C-Calkyl)amino)-ethyl, 3,3,3-trifluoro-propylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2-cyanoethylaminomethyl, morpholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1-azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; Ris hydrogen or halo; Ris hydrogen or halo; provided that at least one of Rand Ris hydrogen; Ris hydrogen, methyl, or halo; and is a single bond that is either present or absent, or pharmaceutically acceptable salt thereof. 

Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer

A compound according to formula II and the pharmaceutically acceptable salts thereof and the method of treating cancer in a patient in need thereof by administration of said compound. 

Quinolinyl-pyrrolopyrazoles

The present invention provides a compound of the formula: (Formula I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.

Mixed lineage kinase modulators

The present invention is directed to inhibitors of TGF-&#x3b2; of Formula I: 

TGF-&#x3b2; inhibitors

The current invention relates to compounds of the formula: (Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds. 

Compounds as pharmaceutical agents

Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.

Pyrazolopyridine derivatives as pharmaceutical agents

A compound according to formula II and the pharmaceutically acceptable salts thereof and the method of treating cancer in a patient in need thereof by administration of said compound.

A novel class of tricyclic compounds of the following formula (I) is disclosed together with the use of such compounds for inhibiting sPLAmediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

[object Object]

This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Aromatic amides

Compounds of the general structural formula and use of the compounds and salts and solvates thereof, as therapeutic agents.

Carboline derivatives

Compounds of general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents as inhibitors of phosphodiesterase 5 cardiovascular disorders 

Chemical compounds

Growing community of inventors

Indianapolis, IN, United States of America

Jason Scott Sawyer